| 证券代码 | NTRP.O |
| 证券名称 | Neurotrope Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2017-03-29 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Neurotrope, Inc. |
| 注册地址 | 美国内华达州 |
| 办公地址 | 205 East 42nd Street – 16th Floor, New York, New York, USA |
| 成立日期 | 2013-08-09 |
| 董事会主席 | Joshua N. Silverman |
| 公司属地 | United States 美国 |
| 公司网址 | www.neurotropebioscience.com |
| 电话 | +1 (973) 242-0005 |
| 传真 | - |
| 公司简介 | Neurotrope, Inc. is a biopharmaceutical company with product candidates in pre-clinical and clinical development. Neurotrope BioScience began operations in October 2012. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (“AD”), which is in the clinical testing stage. It is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C, which are in pre-clinical testing. |